Effects of conjugated linoleic acid (CLA) on development of atherosclerosis in ApoE/LDLr-/- mice
More details
Hide details
Department of Human Nutrition, Faculty of Food Technology, Agricultural University, Cracow, Poland
Department of Histology, Jagiellonian University Medical College, Cracow, Poland
Department of Experimental Pharmacology, Jagiellonian University Medical College, Cracow, Poland
J Pre Clin Clin Res. 2010;4(2):87–91
The effect of conjugated linoleic acid (CLA) on development of atherosclerosis in genetically modified mice ApoE/LDLr -/- was studied. Animals were divided into 2 groups: control (standard AIN-93G diet) (n=8) and CLA (AIN-93G supplemented with 0.5% CLA) (n=6). After 2 months of feeding plasma lipid profile, glucose concentration, liver fatty acid composition and quantification of atherosclerosis were analyzed. In the CLA group, decreased body mass was observed. Plasma total cholesterol and triacylglycerols levels were significantly higher in animals fed CLA compared to Control. There was no effect of CLA on liver and kidney weights, nor on lipid profiles of adipose tissue. Plasma glucose levels were unchanged after CLA feeding. No effect of CLA on atherosclerosis was observed. These results indicate that dietary CLA reduced body mass and increased plasma TC and TAG level. This might be caused by decrease in adipose tissue mass and increase in liver lipogenesis in ApoE/LDLr-/- mice.
Renata B. Kostogrys
Department of Human Nutrition, Faculty of Food Technology, Agricultural University, Balicka 122, 30-149 Cracow, Poland
1. Naruszewicz M: Jak chronić środbłonek naczyniowy w przypadkach występowania hipertriglicerydemii. Zespół metaboliczny 2007, 24-27.
2. Griinari JM, Bauman DE: Biosynthesis of conjugated linoleic acid and its incorporation into meat and milk in ruminants. In: Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, Nelson GJ (Eds.): Advances in Conjugated Linoleic Acid Research 1999, AOCS Press, Champaign (IL), 180-199.
3. Evans M, Brown J, McIntosh M: Isomer-specific effects of conjugated linoleic acid (CLA) on adiposity and lipid metabolism. J Nutr Biochem 2002, 13, 508-516.
4. Terpstra AH, Javadi M, Beynen AC, Kocsis S, Lankhorst AE, Lemmens AG, Mohede IC: Dietary conjugated linoleic acids as free fatty acids and triacylglycerols similarly affect body composition and energy balance in mice. J Nutr 2003, 133, 3181-3186.
5. Wang Y, Jones PJH: The role of conjugated linoleic acid in human health. Dietary conjugated linoleic acid and body composition. Am J Clin Nutr 2004, 79, 1153S-1158S.
6. Gaullier JM, Halse J, Hoje K, Kristiansen K, Fagertun H, Vik H, Gudmundsen O: Supplementation with conjugated linoleic acid for 24 moths is well tolerated by reduces body fat mass in healthy, overweight humans. J Nutr 2005, 135, 778-784.
7. Belury MA: Inhibition of carcinogenesis by conjugated linoleic acid: potential mechanisms of action. J Nutr 2002, 132, 2995-2998.
8. Field CJ, Schley PD: Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids. Am J Clin Nutr 2004, 79, 1190S-1198S.
9. Cho HJ, Kim EJ, Lim SS, Kim MK, Sung MK, Kim JS, Park JHY: Trans- 10, cis-12, not cis-9,trans-11, conjugated linoleic acid inhibits G1-S progression in HT-29 human colon cancer cells. J Nutr 2006, 136, 893-898.
10. O’Shea M, Bassaganya-Riera J, Mohede ICM: Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr 2004, 79, 1199S- 1206S.
11. Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Grimble RF, Williams ChM, Calder PC, Yaqoob P: Effects of cis-9, trans-11 and trans-10, cis-12 conjugated linoleic acid on immune cell function in healthy humans. Am J Clin Nutr 2004a, 80, 1626-1633.
12. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK: Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am Coll Nutr 2000, 19, 472S-477S.
13. Kritchevsky D, Tepper SA, Wright S, Czarnecki SK: Influence of graded levels of conjugated linoleic acid (CLA) on experimental atherosclerosis in rabbits. Nutrition Research 2002, 22, 1275-1279.
14. Noone EJ, Roche HM, Nugent AP, Gibney MJ: The effect of dietary supplementation using isomeric blends of conjugated linoleic acid on lipid metabolism in healthy human subjects. Br J Nutr 2002, 88, 243- 251.
15. Tricon S, Burdge GC, Kew S, Banerjee T, Russell JJ, Jones EL, Grimble RF, Williams CM, Yaqoob P, Calder PC: Opposing effects of cis-9,trans- 11 and trans-10,cis-12 conjugated linoleic acid on blood lipids in healthy humans. Am J Clin Nutr 2004b, 80, 614-620.
16. Valeille K, Gripois D, Blouquit MF, Souidi M, Riottot M, Bouthegourd JC, Serougne C, Martin JC: Lipid atherogenic risk markers can be more favourably influenced by the cis-9 trans-11-octadecadienoate isomer than a conjugated linoleic acid mixture or fish oil in hamsters. Brit J Nutr 2004, 91, 191-199.
17. Arbones-Mainar JM, Navarro MA, Acin S, Guzman MA, Arnal C, Surra JC, Carnicer R, Roche HM, Osada J: Trans-10, cis-12- and cis-9, trans-11-Conjugated Linoleic Acid Isomers Selectively Modify HDLApolipoprotein Composition in Apolipoprotein E Knockout Mice. J Nutr 2006, 136, 353-359.
18. Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O: Profound resolution of early atherosclerosis with conjugated linoleic acid. Atherosclerosis 2006, 187, 40-49.
19. Jawien J, Gajda M, Rudling M, Mateuszuk L, Olszanecki R, Guzik TJ, Cichocki T, Chlopicki S, Korbut R: Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. Eur J Clin Invest 2006a, 36, 141- 146.
20. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R: Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 2005, 56, 627-635.
21. Jawien J, Csanyi G, Gajda M, Mateuszuk L, Lomnicka M, Korbut R, Chlopicki S: Ticlopidine attenuates progression of atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice. Eur J Pharmacol (in press).
22. Reeves PG, Nielsen FH, Fahey GC. AIN-93 purified diets for laboratory rodents: Final report of the American Institute of Nutrition ad hoc Writing Committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993, 123, 1939-1951.
23. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102, 910-918.
24. Elhage R, Jawien J, Rudling M, Ljunggren HG, Takeda KS, Akira S, Bayard F, Hansson GK: Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E – knockout mice. Cardiovasc Res 2003, 59, 234-240.
25. Robertson AK, Rudling M, Zhou X, Gorelik L, Flavell RA, Hansson GK: Disruption of TGF-beta signaling in T cells accelerates atherosclerosis. J Clin Invest 2003, 112, 1342-1350.
26. Ryder JW, Portocarrero CP, Song XM, et al.: Isomer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance, skeletal muscle insulin action, and UCP-2 gene expression. Diabetes 2001, 50, 1149–1157.
27. Park Y, Pariza M.W: Mechanisms of body fat modulation by conjugated linoleic acid (CLA). Food Res Int 2007, 40, 311-323.
28. Park Y, Albright KJ, Storkson JM, Liu W, Cook ME, Pariza MW: Changes in body composition in mice during feeding and withdrawal of conjugated linoleic acid. Lipids 1999, 34, 243-248.
29. West DB, Delany JP, Camet PM, Blohm F, Truett AA, Scimeca J: Effects of conjugated linoleic acid on body fat and energy metabolism in the mouse. Am J Physiol 1998, 275, R667-672.
30. Stangl GI: Conjugated linoleic acid exhibit a strong fat-to-lean partitioning effect, reduce serum VLDL lipids and redistribute tissue lipids in food-restricted rats. J Nutr 2000, 130, 1140-1146.
31. .Park Y, Pariza MW: Mechanisms of body fat modulation by conjugated linoleic acid (CLA). Food Res Int 2007, 40, 311-323.
32. Park Y: Conjugated linoleic acid (CLA): Good or bad trans fat? J Food Com Anal 2009, 22S, S4-S12.
33. Bouthegourd JC, Even PC, Gripois D, Tiffon B, Blouquit MF, Roseau S, Lutton C, Tome D, Martin JC: A CLA mixture prevents body triglyceride accumulation without affecting energy expenditure in Syrian Hamsters. The Journal of Nutrition 2002, 132, 2682-2689.
34. Nestel P, Furii A, Allen T: The cis-9,trans-11 isomer of conjugated linoleic acid (CLA) lowers plasma triglyceride and raises HDL cholesterol concentrations but does not suppress aortic atherosclerosis in diabetic apoE-deficient mice. Atherosclerosis 2006, 189, 282-287.
35. Belury MA, Moya-Camarena SY, Liu KL, Vander Heuvel JP: Dietary conjugated linoleic acid induces peroxisome-specific enzyme accumulation and ornithine decarboxylase activity in mouse liver. J Nutr Biochem 1997, 8, 579-584.
36. Lee KN, Kritchevsky D, Pariza MW: Conjugated linoleic acid and atherosclerosis in rabbits. Atherosclerosis 1994, 108, 19-25.
37. Nicolosi RJ, Rogers EJ, Kritchevsky D, Scimeca JA, Huth PJ: Dietary conjugated linoleic acid reduces plasma lipoproteins and early atherosclerosis in hypercholesterolemic hamsters. Artery 1997, 22, 266-277.
38. Munday JS, Thompson KG, James KAC: Dietary conjugated linoleic acids promote fatty streak formation in the C57BL/6 mouse atherosclerosis model. Br J Nutr 1999, 81, 251-255.
39. Corino C, Fiego DP Lo, Macchioni P, Pastorelli G, Di Giancamillo A, Domeneghini C, Rossi R: Influence of dietary conjugated linoleic acids and vitamin E on meat quality, and adipose tissue in rabbits. Meat Science 2007, 76, 19-28.
40. Cooper MH, Miller JR, Mitchell PL, Currie DL, McLeod RS: Conjugated linoleic acid isomers have no effect on atherosclerosis and adverse effect on lipoprotein and liver lipid metabolism in apoE-/- mice fed a highcholesterol diet. Atherosclerosis 2008, 200(2), 294-302.